Patients typically achieve a 15 to 20 percent reduction in body weight
Liraglutide is in close structural homology to native GLP-1 and is conjugated to a palmitic acid to prolong its half-life for QD administration [3]
The evidence suggests that weight loss is the primary driver of the reproductive improvements seen with semaglutide, as substantial weight reduction is known to improve hormone balance, ovarian function and fertility in women with PMOS. Clare Thompson, MBBS, BSc, nMRCGP However, GLP-1 drugs may also have direct effects on reproductive health via mechanisms such as insulin signalling and ovarian function
At our clinic in Doral, we treat BPC-157 as a prescribed protocol, not a product you buy off a website
The most significant clinical evidence for retatrutide to date comes from a Phase 2 randomised, double-blind, placebo-controlled trial published in the New England Journal of Medicine in 2023 (Jastreboff et al.)